B cells as a therapeutic target in autoimmune disease
AUTOR(ES)
Goronzy, Jörg J
FONTE
BioMed Central
RESUMO
Depleting B cells with anti-CD20 monoclonal antibodies emerges as a new therapeutic strategy in autoimmune diseases. Preliminary clinical studies suggest therapeutic benefits in patients with classic autoantibody-mediated syndromes, such as autoimmune cytopenias. Treatment responses in rheumatoid arthritis have opened the discussion about whether mechanisms beyond the removal of potentially pathogenic antibodies are effective in B-cell depletion. B cells may modulate T-cell activity through capturing and presenting antigens or may participate in the neogenesis of lymphoid microstructures that amplify and deviate immune responses. Studies exploring which mechanisms are functional in which subset of patients hold the promise of providing new and rational treatment approaches for autoimmune syndromes.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=165047Documentos Relacionados
- Escherichia coli msbB Gene as a Virulence Factor and a Therapeutic Target
- H-channels as a Therapeutic Target in Epilepsy
- A possible therapeutic target for Lou Gehrig's disease
- HER2 expression in cervical cancer as a potential therapeutic target
- Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome.
